semaglutide injection site pain Injecting Semaglutide: A Guide to Sites and Technique Where and how to inject

(A link to the article is included in the downloadable course document)

GLP-1 ,

Consultation with a hepatologist is appropriate for patients with advanced liver disease, decompensation signs, or uncertain diagnoses

oral daily (Rybelsus) Tirzepatide Weekly injection (Mounjaro/Zepbound) Trial weight loss Tesofensine About 10% at 0.5 mg over 24 weeks (Phase 2 and Phase 3) Semaglutide About 15% over 68 weeks (STEP trials) Tirzepatide About 21% over 72 weeks (SURMOUNT trials) FDA status (June 2026) Tesofensine Not approved for any indication Semaglutide Approved (Wegovy for obesity, Ozempic for type 2 diabetes) Tirzepatide Approved (Zepbound for obesity, Mounjaro for type 2 diabetes) Main safety concern Tesofensine Heart rate rise, insomnia, mood Semaglutide Nausea, GI upset, rare pancreatitis Tirzepatide Nausea, GI upset, rare pancreatitis Direct head-to-head trials between tesofensine and GLP-1 drugs have not been run

Environmental advocates argue that previous fines were too low to deter chronic polluters, causing DNREC to focus more on compliance than enforcement because of high appeal costs

They offer significant benefits in terms of weight loss and blood sugar control, which can help reduce many obesity-related health complications